Nature Medicine is an academic journal publishing research articles, reviews, news and commentaries in the biomedical area, including both basic research and early-phase clinical research. Topics covered include cancer, cardiovascular disease, gene therapy, immunology, vaccines, and neuroscience. The journal seeks to publish research papers that demonstrate novel insight into disease processes, with direct evidence of the physiological relevance of the results. Founded in 1995, Nature Medicine is published by the Nature Publishing Group, a division of Macmillan Publishers Ltd, and is one of the rapidly expanding stable of Nature journals. As with other Nature journals, there is no external Editorial Board, with editorial decisions being made by an in-house team, although peer review by external expert referees forms a part of the review process. Nature Medicine is published monthly. Articles are archived online in text and PDF formats; access is by subscription only. Its 2010 impact factor was 25.430, making it the highest-cited research journal in preclinical medicine. It is also among the highest impact of primary (non-review) scientific journals.

Publisher
Nature Publishing Group
History
1995--present
Website
http://www.nature.com/nm/index.html
Impact factor
25.430 (2010)

Some content from Wikipedia, licensed under CC BY-SA

Coronaviruses are masters of mimicry, new study finds

Coronaviruses are adept at imitating human immune proteins that have been implicated in severe COVID-19 disease, a study from researchers at Columbia University Vagelos College of Physicians and Surgeons has found.

The evolution of genetic engineering

Charles Gersbach, the Rooney Family Associate Professor of Biomedical Engineering at Duke University, leads a lab that is centered on developing and applying genome engineering tools––most notably CRISPR-based technology. ...

Synthetic phages with programmable specificity

ETH researchers are using synthetic biology to reprogram bacterial viruses—commonly known as bacteriophages—to expand their natural host range. This technology paves the way for the therapeutic use of standardized, synthetic ...

CRISPR's growing pains

In the six years since its inception, CRISPR gene editing has experienced ups and downs, from giddy excitement over the technology's potential to cure genetic diseases to patent disputes, ethical considerations and cancer ...

page 1 from 1